ASCO 2018: Pembrolizumab vs. Chemotherapy as First-line Therapy for Advanced Non-Small Cell Lung Cancer
7 Jun, 2018 | 02:20h | UTCCommentaries: 2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More – The ASCO Post (free) AND ‘End of an Era’ for Chemo in Non-Small Cell Lung Cancer – Medscape (free registration required)